Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 10,601–10,700 of 15,747
Mohammadi, M., Saha, A., Giles‐Davis, W., Xiang, Z., Novikov, M., Hasanpourghadi, M., & Ertl, H. C. J. (2024) · Vaccines · doi:10.3390/vaccines12060616 · Cited by 5
“Although mRNA vaccines are versatile and induce robust immune responses as demonstrated during the COVID-19 pandemic [47,48], they have some disadvantages.”
BackgroundHogarth, M. A., John, D., Li, Y., Wang‐Rodriguez, J., Chakladar, J., Li, W. T., Mehta, S. R., Jain, S., & Ongkeko, W. M. (2023) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2023.04.019 · Cited by 4
“D.(1), Daniel John(2,3), Yuxiang Li(2,3), Jessica Wang-Rodriguez, M.”
Unvaccinated COVID-19 Pneumonia- a family affair
Stead, T., Hughes, M., Fraunfelter, F., Rodriguez, V., & Ganti, L. (2022) · Health Psychology Research · doi:10.52965/001c.34153 · Cited by 3
Landa, C., Reséndiz‐Mora, A., Sánchez-Barbosa, S., Sotelo-Rodríguez, A., Barrera-Aveleida, G. B., Nevárez‐Lechuga, I., Galarce-Sosa, I., Taniguchi‐Ponciano, K., Cruz‐Guzmán, O. D. R., Wong‐Baeza, I., et al. (2022) · Membranes · doi:10.3390/membranes12070643 · Cited by 3
“For example, in the mRNA-based vaccines against COVID-19, the mRNA that encodes the coronavirus spike protein is encapsulated in liposomes [7,8].”
BackgroundAdhMMP8 Vector Administration in Muscle: An Alternate Strategy to Regress Hepatic Fibrosis
Garcia-Bañuelos, J. J., Oceguera-Contreras, E., Sandoval-Rodriguez, A. S., Bastidas‐Ramírez, B. E., Lucano‐Landeros, S., Gordillo‐Bastidas, D., Gómez‐Meda, B. C., Santos, A., Reyes, E. C., & Armendáriz‐Borunda, J. (2023) · Cells · doi:10.3390/cells12172127 · Cited by 4
“At least four of the most used effective and safe vaccines are mRNA-1273, Moderna [1], BNT162b2, Pfizer/BioNTech [2], AZD1222, Oxford/AstraZeneca (Voysey 2021), Ad26.”
BackgroundAnalyzing public perception toward COVID-19 vaccines in Indonesia
Rizqiyah, P., Yulianti, E., & Jiwanggi, M. A. (2023) · International Journal of Public Health Science (IJPHS) · doi:10.11591/ijphs.v13i1.23134 · Cited by 3
“The score rose in on November 27, 2021 in response to tweets claiming that Sinopharm had obtained an emergency use permit for 2021 [36].”
BackgroundChen, Z., Wan, C., Chen, B. Y., Mo, Q., Ju, M., Deng, K., Li, X., & Qin, D. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1668576 · Cited by 4
Keats, K. R., LaCoursiere, R. J., Forehand, C. C., et al. (2022) · Currents in Pharmacy Teaching and Learning · doi:10.1016/j.cptl.2022.06.025 · Cited by 3
Zhang, P., Cai, Z., He, Z., Chen, P., Wu, W., Lin, Y., Feng, S., Peng, L., Li, J., Yuan, J., et al. (2022) · European journal of medical research · doi:10.1186/s40001-022-00927-1 · Cited by 3
“[1] The interval between the last blood collection and the date of admission in hospital”
BackgroundNavigating the landscape of epitranscriptomics and host immunity
Huang, E., Frydman-Gani, C., & Xiao, X. G. (2024) · Genome Research · doi:10.1101/gr.278412.123 · Cited by 6
Comparison of Outcomes between Vaccinated versus Non-Vaccinated Covid-19 Patients
Safdar, T., Shafqat, F., Ansari, A. M., Ali, A., Bilal, M., & Imran, M. A. (2021) · Pakistan Journal of Medical and Health Sciences · doi:10.53350/pjmhs211592572 · Cited by 3
“Vaccine development has accelerated to unprecedented levels to combat the growing threat of COVID-19 [5].”
The role of intestinal microbiota in the humoral response to SARS-CoV-2 after mRNA-1273 vaccination
Tarriño-León, M., Gutiérrez‐Bautista, J. F., Durán, M. J. O., García-Díaz, A., Cabrera-Serrano, A. J., Sáinz, J., Cobo, F., Rodríguez, T., Reguera, J. A., Bernal, M., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-11103-w · Cited by 4
“This is due to the great impact on the reduction of severe illness and mortality 2,3 .”
A review of SARS-CoV-2 virology, vaccines, variants and their impact on the COVID-19 pandemic
Hirahata, T., Quraish, R. U., Quraish, A. U., & Quraish, S. U. (2024) · Reviews in Medical Microbiology · doi:10.1097/mrm.0000000000000393 · Cited by 5
Bilateral anterior uveitis after BNT162b2 mRNA vaccine: Case report
Duran, M. (2022) · Journal Français d Ophtalmologie · doi:10.1016/j.jfo.2022.04.004 · Cited by 3
Kociszewska‐Najman, B., Jaskólska, M., Taradaj, K., Sibanda, E., & Ginda, T. (2022) · Vaccines · doi:10.3390/vaccines10071089 · Cited by 3
“COVID-19 vaccines are safe and highly effective in the prevention of SARS-CoV-2 infections [2].”
BackgroundVeereman, G., & Bronský, J. (2021) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000003260 · Cited by 3
Busà, R., Miele, M., Sorrentino, M. C., Amico, G., Timoneri, F., Miceli, V., Bella, M. D., Russelli, G., Gallo, A., Zito, G., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315046 · Cited by 5
Hassan, E. W. E., AbuAlhommos, A. K., Aliadhy, D., Alsalman, S., Alnafaa, O., & Mohamed, A. R. (2022) · Healthcare · doi:10.3390/healthcare10050853 · Cited by 5
“Multiple vaccines have been proven through multicenter randomized controlled trials to be safe and effective in decreasing the incidence and severity of COVID-19 infection [10].”
BackgroundImpfung gegen SARS-CoV-2 bei Krebspatienten
von Lilienfeld‐Toal, M., Rieger, C. T., Giesen, N., & Wormann, B. J. (2021) · Der Onkologe · doi:10.1007/s00761-021-00972-1 · Cited by 3
Walmsley, S. L., Nabipoor, M., Chao, G. Y. C., Lovblom, L. E., Ward, L. A., Ravindran, R., Colwill, K., Gingras, A., & Gommerman, J. L. (2025) · ImmunoHorizons · doi:10.1093/immhor/vlaf068 · Cited by 3
Impact of the COVID-19 pandemic on bone and soft tissue tumor treatment: A single-institution study
Ban, Y., Hoshi, M., Oebisu, N., Shimatani, A., Takada, N., Iwai, T., & Nakamura, H. (2023) · PLoS ONE · doi:10.1371/journal.pone.0283835 · Cited by 3
“The American pharmaceutical giant Pfizer developed the vaccine in collaboration with Biontech (the German biotech company) [8], and vaccinations began in the UK in December 2020 [9].”
Motives for Vaccination Against COVID-19 Among the Ultra-orthodox Jewish Community in Israel
Schiff, M., & Sharon-Lavi, N. (2024) · Journal of Religion and Health · doi:10.1007/s10943-024-02018-3 · Cited by 4
“The Pfizer vaccine imported to Israel by the Israeli Ministry of Health was 95% effective in preventing severe illness from the virus when two doses were provided (Dagan et al., 2021; Polack et al., 2020).”
Micek, A., Diehl, K., Teuscher, M., Schaarschmidt, M., Sasama, B., Ohletz, J., Burbach, G. J., Kiecker, F., Hillen, U., Harth, W., et al. (2022) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.14799 · Cited by 3
Acute pericarditis and cardiac tamponade after COVID-19 vaccination
Shen, X., Koh, S. H. M., Lim, B. Y., et al. (2021) · Singapore Medical Journal · doi:10.11622/smedj.2021195 · Cited by 3
“[4] To the best of our knowledge, this is the first reported case of Pfizer–BioNTech COVID‑19 vaccine‑related acute pericarditis complicated by cardiac tamponade.”
BackgroundRomantowski, J., Nazar, W., Bojahr, K., Popiołek, I., & Niedoszytko, M. (2024) · Life · doi:10.3390/life14060715 · Cited by 3
“The ensuing rapid, one-year-long vaccine development process has made societies uneasy about vaccination safety [3–6].”
BackgroundQuantifying the impact of a broadly protective sarbecovirus vaccine in a future SARS-X pandemicPreprint
Whittaker, C. A., Barnsley, G., Mesa, D. O., et al. (2024) · medRxiv · doi:10.1101/2024.08.12.24311730 · Cited by 3
Robinson, J. M., Gomez, P. L., Rogalewicz, J. A., Havelange, N., Sitrin, R. D., & Gervier, R. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-79058-1.00006-2 · Cited by 4
Impact of ChAdOx1 nCoV-19 (Covishield™) Vaccination: How Long Will It Persist?
Devi, L. S., Sardar, M., Sharma, M., & Khandait, M. (2022) · International Journal of Microbiology · doi:10.1155/2022/4729844 · Cited by 3
Cheung, C. K. M., Law, K. W. T., Law, A. W. H., Law, M. F., Ho, R., & Wong, S. H. (2023) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2022.00339 · Cited by 3
The Role of SARS-CoV-2 Spike Protein in the Growth of Cervical Cancer Cells
Willson, C. M., Lequio, M., Zhu, Z., Wakefield, M. R., Bai, Q., Fajardo, E., XIAO, H., Leung, S., & Fang, Y. (2024) · Anticancer Research · doi:10.21873/anticanres.16982 · Cited by 6
Markus, A. F., Strauss, V. Y., Burn, E., Li, X., Delmestri, A., Reich, C., Yin, C., Mayer, M. Á., Ramírez‐Anguita, J. M., Martí, E., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1118203 · Cited by 3
“COVID-19 vaccines have shown great effectiveness in preventing severe COVID-19 disease, a disease which lead to hospitalizations and related deaths (Polack et al., 2020; Baden et al., 2021; Voysey et al., 2021).”
BackgroundCOVID-19 vaccine type controls stromal reprogramming in draining lymph nodes
Fair-Mäkelä, R., Thorén, P., Näsiaho, J., Sundqvist, P., Piiroinen, I., Kähäri, L., Julkunen, I., Ivaska, J., Hub, E., Rot, A., et al. (2025) · Science Immunology · doi:10.1126/sciimmunol.adr6787 · Cited by 6
Su, W., Chan, K. A., Chuang, J.-H., Wang, T.-A., Chen, S.-F., Chang, Y.-C., Chen, M., Chang, C.-C., & Yang, C.-H. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.03.042 · Cited by 3
“6 years; MVC, mean age = 45 years) clinical trial subjects [19-22].”
BackgroundTschiderer, L., Seekircher, L., Richter, L., von Laer, D., Lass-Flörl, C., Forer, L., Schönherr, S., Krammer, F., Embacher-Aichhorn, S., Tilg, H., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105380 · Cited by 2
Matsunaga, H., Takeuchi, H., Oba, Y., Fujimi, S., Honda, T., & Tomonaga, K. (2022) · Vaccines · doi:10.3390/vaccines10020177 · Cited by 6
“A study of the clinical efficacy of the BNT162b2 vaccine found that it prevented 95% of infections 90 days after the second vaccination [4].”
BackgroundVaccine and the Need To Be Heard: Considerations for COVID-19 Immunization in ESKD
Srivatana, V., Wilkie, C. M., Perl, J., et al. (2021) · Kidney360 · doi:10.34067/kid.0001932021 · Cited by 3
Vartanian, K. B., Fish, D., Gronowski, B., Kenton, N. R., & Robicsek, A. A. (2022) · Patient · doi:10.1007/s40271-022-00605-8 · Cited by 3
Gullo, R. L., Lambert, C. C., Lin, O., et al. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06473-4 · Cited by 3
“Most recently, data from COVID-19 vaccination suggest a higher immunogenic power of this vaccine, having shown higher rates of unilateral axillary lymphadenopathy [7, 8].”
BackgroundRavindran, R. K., Kang, H., McReynolds, C. B., Sanghar, G. K., Chang, W. L. W., Ramasamy, S., Kolloli, A., Kumar, R., Subbian, S., Hammock, B. D., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0287377 · Cited by 4
Raczkiewicz, P., Trojnar, M. P., Zaremba, B., & Śmiech, N. (2021) · Medycyna Ogólna i Nauki o Zdrowiu · doi:10.26444/monz/143362 · Cited by 3
“Monitoring the safety of patients will be continued for two years after administration of the second dose of vaccine [12, 13].”
BackgroundResultInfluentialWang, Z., Röst, G., & Moghadas, S. M. (2024) · Royal Society Open Science · doi:10.1098/rsos.231971 · Cited by 3
Tsoi, H., Ng, M. K.-W., Cai, J., Poon, R. W., Chan, B. P.-C., Chan, K., Tam, A. R., Chu, W.-M., Hung, I. F., & To, K. K. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e35334 · Cited by 4
“Consistent with the serum antibody and T cell results, the vaccine efficacy of CoronaVac vaccine against symptomatic COVID-19 was much lower than those of BNT162b2 vaccine during the phase 3 randomized controlled trials [24,25].”
Wang, T., Cayetano, K., Parvataneni, C. K., Paranada, K., Sanchez-Metz, C., & Haws, C. R. (2021) · Infectious Diseases in Clinical Practice · doi:10.1097/ipc.0000000000001097 · Cited by 3
Yukishima, T., Ohmura, S., Yonezawa, H., Ueyama, A., Sato, S., Katayama, M., Ohkuma, S., Ostuki, Y., & Ogawa, N. (2024) · Internal Medicine · doi:10.2169/internalmedicine.4197-24 · Cited by 3
de Jong, R., Zhou, F., Andersen, T. K., et al. (2025) · npj Vaccines · doi:10.1038/s41541-025-01341-4 · Cited by 3
Sakurai, A., Marshall, S., Ogasawara, T., Ogasawara, T., Aoka, Y., Sakura, H., Uchigata, Y., & Ogawa, T. (2022) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2022.03.029 · Cited by 3
“Both the Pfizer and Moderna vaccines have been shown to be effective in preventing severe disease [26,27], although deaths due to COVID-19 pneumonia after vaccinations have also been reported [28].”
Sejersen, K., Sütterlin, S., & Larsson, A. O. (2026) · Biomedicines · doi:10.3390/biomedicines14030694 · Cited by 5
Potential of Immune-Related Therapy in COVID-19
Yuan, C., Li, R., Liu, G., & Pan, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.609212 · Cited by 3
Doumeth, S. A., Gong, J. D., Silversteyn, L., et al. (2023) · Vaccine X · doi:10.1016/j.jvacx.2023.100295 · Cited by 3
“[15] Polack FP, Thomas SJ, Kitchin N, et al.”
Meyer, J., Hoerauf, A. M., Dubiel, A. E., Kovačević, P., Trudić, A., Primorac, D., Hübner, M. P., Adjobimey, T., & Parčina, M. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1727049 · Cited by 4
The problematic side of precision medicine: A short voyage through some questions
Boniolo, G. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780198863465.003.0004 · Cited by 3
Adverse events following SARS-CoV-2 mRNA vaccination in norwegian adolescents
Larsen, V. B., Gunnes, N., Gran, J. M., Dahl, J., Bøås, H., Watle, S. V., Berild, J. D., Greve‐Isdahl, M., Størdal, K., Gulseth, H. L., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-45261-2 · Cited by 9
Effectiveness of and Immune Responses to SARS-CoV-2 mRNA Vaccines and Their Mechanisms
Gohda, E. (2022) · Journal of Disaster Research · doi:10.20965/jdr.2022.p0007 · Cited by 3
Zhang, Y., Liu, X.-Z., Zhang, Z., Zhou, T., Zhang, X., Yang, H.-Y., Tan, M., Hu, N., Shi, S.-F., Wang, F., et al. (2021) · National Science Review · doi:10.1093/nsr/nwac034 · Cited by 3
Non-pharmaceutical interventions and inoculation rate shape SARS-CoV-2 vaccination campaign success
Galanti, M., Pei, S., Yamana, T. K., Angulo, F. J., Charos, A., Khan, F. L., Shea, K. M., Swerdlow, D. L., & Shaman, J. L. (2021) · Epidemiology and Infection · doi:10.1017/s095026882100217x · Cited by 4
Cerbino-Neto, J., Peres, I. T., Varela, M. C., Brandão, L. G. P., de Matos, J. A., Pinto, L. F., da Costa, M. D., Garcia, M. H. D. O., Soranz, D., Maia, M. D. L. D. S., et al. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.1017337 · Cited by 2
Association of COVID-19 Case-Fatality Rate With State Health Disparity in the United States
Lee, Y.-C., Chang, K.-Y., & Mirsaeidi, M. S. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.853059 · Cited by 2
Nanoparticle targeting strategies for traumatic brain injury
Flores-Prieto, D. E. E., & Stabenfeldt, S. E. (2024) · Journal of Neural Engineering · doi:10.1088/1741-2552/ad995b · Cited by 5
Rostenberghe, H. V. (2021) · Malaysian Journal of Medical Sciences · doi:10.21315/mjms2021.28.1.17 · Cited by 3
Research advances of liposomes and exosomes in drug delivery and biomarker screening
Su, Y., Qian, X., & Qin, W. (2025) · Chinese Journal of Chromatography · doi:10.3724/sp.j.1123.2024.08012 · Cited by 4
Zhou, Y.-F., Nie, J., Shi, C., Ning, K., Cao, Y., Xie, Y., Xiang, H., & Xie, Q. (2022) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.2205.05023 · Cited by 3
COVID 19 vaccine induced glycaemic disturbances in DM2 -A Case Report
Prasad, A. S. V. (2021) · World Journal of Advanced Research and Reviews · doi:10.30574/wjarr.2021.10.3.0247 · Cited by 3
“It is not intended to review, in this article, the merits and demerits or safety profiles of the various vaccines available for Covid 19, as the same are reviewed extensively, elsewhere [1 -6].”
Müllerová, H., Medin, J., Arnold, M., da Silva, H. G., Kumar, S. R., Nord, M., Hubbard, R., & de Lusignan, S. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-063645 · Cited by 3
Ju, J., Kim, T., Yoon, S., Kim, W. H., & Lee, H. (2024) · Korean Journal of Anesthesiology · doi:10.4097/kja.23761 · Cited by 4
Mumena, D. K., Kwenda, G., Ngugi, C. W., & Nyerere, A. K. (2022) · Journal of Biomedical Research & Environmental Sciences · doi:10.37871/jbres1542 · Cited by 3
Mahoney, M. R., Winget, M., Brown‐Johnson, C. G., Borba, L. D., Veruttipong, D., Luu, J. H., Jones, D. C. L., Bohman, B. D., & Vilendrer, S. M. (2022) · Journal of Healthcare Management · doi:10.1097/jhm-d-21-00226 · Cited by 3
Yasmin, M., Tfaily, M. A., Wazzi-Mkahal, R., Obeid, R., Emery, R. P., Hassouna, H., Bhugra, M., Bonomo, R. A., & Kanafani, Z. A. (2024) · Microorganisms · doi:10.3390/microorganisms12061200 · Cited by 3
“Despite the record time in which the various COVID-19 vaccines were developed and the clinical trials were conducted [1,2], the vaccine rollout was not always as swift.”
BackgroundSIR-based model with multiple imperfect vaccinesPreprint
Aguilar-Canto, F. J., de León, U. A.-P., & Avila-Vales, E. J. (2021) · medRxiv · doi:10.1101/2021.05.07.21256860 · Cited by 3
Bieńkowska, A., & Małecki, M. (2021) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2021.3183 · Cited by 3
COVID-19: Using the Right Tools at the Right Time
Griffin, D. O. (2022) · Medical Research Archives · doi:10.18103/mra.v10i8.3041 · Cited by 4
Cheda, M., Kuczyńska, M., Dąbrowska, I., Sobstyl, J., Szmygin, H., Zarajczyk, A., Materek, M., Rejdak, K., & Drelich‐Zbroja, A. (2024) · Neurologia i Neurochirurgia Polska · doi:10.5603/pjnns.97675 · Cited by 3
Vaccination Strategies for Minimizing Loss of Life in COVID-19 in a Europe Lacking VaccinesPreprint
Hunziker, P. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3780050 · Cited by 7
Mesenchymal Stem Cells and Extracellular Vesicles: An Emerging Alternative to Combat COVID-19
Rodriguez, H. C., Gupta, M., Cavazos-Escobar, E., Montalvo, E., El‐Amin, S. F., & Gupta, A. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.97212 · Cited by 5
Leeyaphan, C., Jirawattanadon, P., Bunyaratavej, S., Panjapakkul, W., Hutachoke, T., Nanchaipruek, Y., & Phumariyapong, P. (2023) · Dermatology Research and Practice · doi:10.1155/2023/2206498 · Cited by 4
A Critical Assessment of COVID-19 Genomic Vaccines
Sabbah, D. A., Hajjo, R., & Sunoqrot, S. (2023) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026623666230825094341 · Cited by 4
Chaparian, R. R., Harding, A. T., Riebe, K. J., Karlsson, A., Sempowski, G. D., Heaton, N. S., & Heaton, B. E. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.30.441968 · Cited by 3
Timing and implications for immune response to vaccine in SARS-CoV-2 breakthrough infections
Arsuffi, S., Sansone, E., Focà, E., Storti, S., Diaferia, T., Bonfanti, C., Terlenghi, L., Caruso, A., Sala, E., Castelli, F., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106716 · Cited by 3
“In phase 3 controlled clinical trial (RCT), BNT162b2 and 1273 showed 95% efficacy against symptomatic COVID-19 7 days after the second dose and large-scale vaccination was applied as the most effective public health measure for control of the COVID-19 pandemic.(8,9)”
MethodRNA ‐Based Therapies for Inherited Metabolic Disorders
Reddy, S. V., Gurung, S., Ghosh, R., Mills, P. B., Baruteau, J., & Zhou, H. (2026) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.70150 · Cited by 7
“…and Spikevax (Moderna) for preventing SARS- CoV-2 infection during the COVID-19 pandemic marked a significant milestone for mRNA-based therapeutics [132, 133]. mRNA technology has evolved significantly since its initial discovery to the development of in vitro-transcribed (IVT) mRNA and the first…”
Ohji, G., Funakoshi, Y., Yakushijin, K., Matsutani, T., Sasaki, T., Kusakabe, T., Matsumoto, S., Koyama, T., Nagatani, Y., Kurata, K., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1468760 · Cited by 4
Significant Publications on Infectious Diseases Pharmacotherapy in 2020
Eubank, T. A., Zaidan, N., Alnezary, F. S., Moc, C., Olson, K., Zaki, A. F., McDaneld, P. M., Gonzales-Luna, A. J., & on behalf of the Houston Infectious Diseases Network (2021) · Journal of Pharmacy Practice · doi:10.1177/08971900211040438 · Cited by 4
“The final rankings of the top 20 general ID/ COVID-19 and 5 HIV/AIDS articles are listed in Table 1 and Table 2, respectively.(14-38) The 11 papers (10 general ID/ COVID-19 and 1 HIV/AIDS) with the highest rankings are summarized below, listed in alphabetical order by the lead author’s last name.”
BackgroundLong-term efficacy of the peptide-based COVID-19 T cell activator CoVac-1 in healthy adults
Tandler, C., Heitmann, J., Michel, T., Marconato, M., Jaeger, S., Tegeler, C. M., Denk, M., Richter, M., Oezbek, M. T., Maringer, Y., et al. (2023) · medRxiv · doi:10.1101/2023.06.07.23291074 · Cited by 16
“developed to reduce transmission and prevent severe disease outcome (1-4).”
BackgroundOlguin-Nava, M., Bohn, P. S., Hennig, T., Börtlein, C., Gribling-Burrer, A.-S., Schmidt, N., Caliskan, N., Dölken, L., Munschauer, M., & Smyth, R. P. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.05.578560 · Cited by 4
“It is because of this, and even with the availability of highly effective vaccines 12–14 , that the epidemic continues to spread rapidly around the world.”
BackgroundEffects of Biological Sex and Pregnancy on SARS-CoV-2 Pathogenesis and Vaccine Outcomes
Shapiro, J. R., Roberts, C. W., Arcovio, K., Reade, L., Klein, S. L., & Dhakal, S. (2023) · Current topics in microbiology and immunology · doi:10.1007/978-3-031-35139-6_4 · Cited by 8
Celebrating vaccines: The 2023 Nobel prize in medicine or physiology
Poland, G. A., & MacIntyre, C. R. (2024) · Vaccine · doi:10.1016/j.vaccine.2023.10.056 · Cited by 3
Mathematical Assessment of the Role of Interventions Against SARS-CoV-2
Safdar, S., & Gumel, A. B. (2023) · Fields Institute communications · doi:10.1007/978-3-031-40805-2_10 · Cited by 3
Sanjeev, A., Reiss, C. W., Politi, J., Beuning, P. J., & Cheng, C. J. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf1124 · Cited by 5
“These compelling attributes provided the foundation for the rapid expansion of the mRNA manufacturing infrastructure over the last decade, which was also largely driven by the global vaccine response during the COVID-19 pandemic [ 8 , 9 ].”
Zaki, H. A., Zahran, A., Abdelrahim, M., Elnabawy, W. A., & Kaber, Y. (2022) · Cureus · doi:10.7759/cureus.21207 · Cited by 3
“It is a known fact that a two-dose regimen of the BNT162b2 vaccine confers at least 95% protection against COVID-19 with a good safety profile [3].”
BackgroundDevelopment of Emerin mRNA Lipid Nanoparticles to Rescue Myogenic Differentiation
Marano, N., Guner, L. E., Riley, R., & Holaska, J. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26167774 · Cited by 4
“LNPs have been studied extensively for nucleic acid delivery both in vitro and in vivo in cancer [33,34], viral indications [35,36], genetic diseases [37], pregnancy [38,39], and more, with several platforms having gained FDA approval [35–37].”
Pienkowski, M. M., & Pienkowski, S. M. (2021) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2021.09.021 · Cited by 3
Ecological comparison of six countries in two waves of COVID-19
Liu, M., Shi, L., Yang, M., Jiao, J., Yang, J., Ma, M., Xie, W., & Sun, G. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1277457 · Cited by 3
“Some scholars have confirmed the effectiveness of BNT162b2 vaccine against COVID-19 infection in their studies and some research results have provided support for high effectiveness of BNT162b2 against hospital admissions up until around 6 months after being fully vaccinated (43, 44).”
ResultGuerrero-Araya, E., Ravello, C., Rosemblatt, M. S., & Pérez‐Acle, T. (2025) · Scientific Reports · doi:10.1038/s41598-024-84260-z · Cited by 4
Niyomnaitham, S., Atakulreka, S., Wongprompitak, P., Copeland, K. K., Toh, Z. Q., Licciardi, P. V., Srisutthisamphan, K., Jansarikit, L., & Chokephaibulkit, K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1080791 · Cited by 3
“Mild scores (1) did not interfere with patients’ activities, moderate scores (2) interfered with patients’ activity, severe scores (3) prevented daily activities, and emergency scores (4) required hospitalization 4 (12).”
Background
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.